Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 16040887

Evidence in practice.

A K Akobeng
View original source ↗Export metadata ↓

Abstract

A clinical scenario is used to illustrate how the principles outlined in the previous articles in the series could be applied to help improve patient care. A practical demonstration of the art of formulating answerable clinical questions, finding evidence, critically appraising evidence, and putting evidence into practice is provided. The importance of integrating evidence with patient's preferences, and taking account of issues such as availability of interventions, costs, and so on is discussed. Finally, some of the issues involved in the development of evidence based policies within clinical teams are outlined.

Explore related subjects

Antibodies, MonoclonalChildChild WelfareCosts and Cost AnalysisCrohn DiseaseDecision MakingEvidence-Based MedicineFamily PracticeGastrointestinal AgentsHumansInfliximabInformation Storage and RetrievalRisk AssessmentJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A K Akobeng. 2005. Evidence in practice.. https://doi.org/10.1136/adc.2004.058248

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2026

ZrO₂@C-based colorimetric/photothermal dual-mode immunosensor coupled with a novel monoclonal antibody for quantification of Aspergillus ochraceus biomass.

Aspergillus ochraceus contaminates agricultural products and produces nephrotoxic, carcinogenic ochratoxin A (OTA), posing severe food safety hazards. A dual-signal lateral flow immunochromatographic assay (dLFIA) based on ZrO₂@C nanoprobes was established for quantitative detection of A. ochraceus biomass. A novel monoclonal antibody (mAb 4B4) was prepared as the capture antibody to immobilize A. ochraceus mycelial lysate antigen on the test line, and a rabbit polyclonal antibody (pAb G2801) as the detection antibody to modify ZrO₂@C composites (synthesized via UiO-66 pyrolysis) into 200 nm colorimetric/photothermal nanoprobes. This dLFIA achieved limits of detection of 0.164 μg/mL (colorimetric) and 0.517 μg/mL (photothermal). This efficient and reliable method allows quantitative analysis of A. ochraceus biomass, which is suitable for routine monitoring of fungal contamination in agro-food matrices.

Antibodies, Monoclonal↗
PubMed2008

Response to rituximab in a child with neuroblastoma and opsoclonus-myoclonus.

Opsoclonus-myoclonus (OM) is a paraneoplastic syndrome of probable autoimmune origin. Despite current therapies aimed at decreasing autoantibody formation, OM is difficult to control and may impact long-term neurologic outcome. We present a case of a 19-month-old patient who initially presented with OM, neuroblastoma and a constitutional cytogenetic abnormality t(5;12)(q11.2;q15). The patient's OM was recalcitrant to conventional therapies, but showed significant improvement following treatment with rituximab.

Antibodies, Monoclonal↗
PubMed2006

Accurate identification of HER2-positive patients is essential for superior outcomes with trastuzumab therapy.

PURPOSE/OBJECTIVES: To review the clinical significance, methods of testing, and outcomes of trastuzumab (Herceptin) treatment for HER2 gene amplification and HER2 protein overexpression in breast cancer. DATA SOURCES: Published articles and abstracts, online resources, a clinical handbook, and product information. DATA SYNTHESIS: HER2 gene amplification or HER2 protein overexpression can be found in 20%-25% of breast cancers and is important pathogenic and prognostic information. HER2 also predicts patient response to trastuzumab. Patients with HER2-positive metastatic breast cancer benefit from trastuzumab whether selected by immunohistochemistry, which measures the HER2 protein, or fluorescence in situ hybridization (FISH), which measures the HER2 oncogene. However, patients who are identified accurately as HER2 gene-amplified by FISH derive the greatest benefit. CONCLUSIONS: Accurate testing is crucial for appropriate identification of patients for trastuzumab therapy. FISH is the most reproducible and accurate method. IMPLICATIONS FOR NURSING: Education regarding HER2 testing and trastuzumab helps patients to make informed decisions and facilitates active participation in their care as well as enhances dialogue with physicians.

Antibodies, Monoclonal↗